Literature DB >> 26648614

Long-term drug treatment of patients with alcohol dependence.

Philip Crowley1.   

Abstract

Drug therapy for alcohol dependence should only be used in conjunction with a comprehensive treatment plan. Naltrexone and acamprosate have well established efficacy and are first-line treatments. Naltrexone is recommended for patients aiming to cut down their alcohol intake who do not have severe liver disease or an ongoing need for opioids. Acamprosate is recommended for those who have achieved and wish to maintain abstinence. Disulfiram is no longer considered first-line treatment due to difficulties with compliance and toxicity. Although baclofen and topiramate have evidence of benefit, they are not registered for alcohol dependence and should only be considered in specialist practice.

Entities:  

Keywords:  acamprosate; alcohol dependence; baclofen; disulfiram; naltrexone; topiramate

Year:  2015        PMID: 26648614      PMCID: PMC4653998          DOI: 10.18773/austprescr.2015.015

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


  17 in total

Review 1.  The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.

Authors:  Helen M Pettinati; Charles P O'Brien; Amanda R Rabinowitz; Shoshana P Wortman; David W Oslin; Kyle M Kampman; Charles A Dackis
Journal:  J Clin Psychopharmacol       Date:  2006-12       Impact factor: 3.153

Review 2.  Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

Authors:  Bankole A Johnson; Nassima Ait-Daoud
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

3.  Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection.

Authors:  L Leggio; A Ferrulli; A Zambon; F Caputo; G A Kenna; R M Swift; G Addolorato
Journal:  Addict Behav       Date:  2011-12-27       Impact factor: 3.913

Review 4.  Antispasticity drugs: mechanisms of action.

Authors:  R A Davidoff
Journal:  Ann Neurol       Date:  1985-02       Impact factor: 10.422

Review 5.  The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.

Authors:  Barbara J Mason; Charles J Heyser
Journal:  Expert Opin Drug Saf       Date:  2010-01       Impact factor: 4.250

6.  Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials.

Authors:  Manit Srisurapanont; Ngamwong Jarusuraisin
Journal:  Int J Neuropsychopharmacol       Date:  2005-06       Impact factor: 5.176

7.  Reduction of alcohol's reinforcing and motivational properties by the positive allosteric modulator of the GABA(B) receptor, BHF177, in alcohol-preferring rats.

Authors:  Paola Maccioni; Mauro A M Carai; Klemens Kaupmann; Sébastien Guery; Wolfgang Froestl; Kimberly A Leite-Morris; Gian Luigi Gessa; Giancarlo Colombo
Journal:  Alcohol Clin Exp Res       Date:  2009-07-01       Impact factor: 3.455

8.  Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.

Authors:  Giovanni Addolorato; Lorenzo Leggio; Anna Ferrulli; Silvia Cardone; Luisa Vonghia; Antonio Mirijello; Ludovico Abenavoli; Cristina D'Angelo; Fabio Caputo; Antonella Zambon; Paul S Haber; Giovanni Gasbarrini
Journal:  Lancet       Date:  2007-12-08       Impact factor: 79.321

Review 9.  Acamprosate: recent findings and future research directions.

Authors:  Karl Mann; Falk Kiefer; Rainer Spanagel; John Littleton
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

10.  Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration.

Authors:  A C Del Re; Adam J Gordon; Anna Lembke; Alex H S Harris
Journal:  Addict Sci Clin Pract       Date:  2013-07-08
View more
  6 in total

1.  High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.

Authors:  John C Crabbe; Angela R Ozburn; Pamela Metten; Amanda Barkley-Levenson; Jason P Schlumbohm; Stephanie E Spence; Wyatt R Hack; Lawrence C Huang
Journal:  Pharmacol Biochem Behav       Date:  2017-08-05       Impact factor: 3.533

2.  In-Hospital Patient Education Markedly Reduces Alcohol Consumption after Alcohol-Induced Acute Pancreatitis.

Authors:  Rita Nagy; Klementina Ocskay; Alex Váradi; Mária Papp; Zsuzsanna Vitális; Ferenc Izbéki; Eszter Boros; László Gajdán; Andrea Szentesi; Bálint Erőss; Péter Jenő Hegyi; Áron Vincze; Judit Bajor; Patricia Sarlos; Alexandra Mikó; Katalin Márta; Dániel Pécsi; Andrea Párniczky; Péter Hegyi
Journal:  Nutrients       Date:  2022-05-20       Impact factor: 6.706

3.  Validation of differential GDAP1 DNA methylation in alcohol dependence and its potential function as a biomarker for disease severity and therapy outcome.

Authors:  Christof Brückmann; Adriana Di Santo; Kathrin Nora Karle; Anil Batra; Vanessa Nieratschker
Journal:  Epigenetics       Date:  2016-04-29       Impact factor: 4.528

Review 4.  Naltrexone Implant for Opioid Use Disorder.

Authors:  Amber N Edinoff; Catherine A Nix; Claudia V Orellana; Samantha M StPierre; Erin A Crane; Blaine T Bulloch; Elyse M Cornett; Rachel L Kozinn; Adam M Kaye; Kevin S Murnane; Alan D Kaye
Journal:  Neurol Int       Date:  2021-12-30

5.  Tph2 Gene Expression Defines Ethanol Drinking Behavior in Mice.

Authors:  Magdalena Zaniewska; Valentina Mosienko; Michael Bader; Natalia Alenina
Journal:  Cells       Date:  2022-03-03       Impact factor: 6.600

6.  Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial potential.

Authors:  Adriana Castillo-Villanueva; Yadira Rufino-González; Sara-Teresa Méndez; Angélica Torres-Arroyo; Martha Ponce-Macotela; Mario Noé Martínez-Gordillo; Horacio Reyes-Vivas; Jesús Oria-Hernández
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2017-12-01       Impact factor: 4.077

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.